Back to top
more

ImmunoGen, Inc. (IMGN)

(Delayed Data from NSDQ)

$2.88 USD

2.88
5,883,771

+0.38 (15.20%)

Updated May 3, 2019 04:00 PM ET

After-Market: $2.93 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

ImmunoGen Lead Drug Gets Nod for Accelerated Approval Pathway

by Zacks Equity Research

FDA approves a new pivotal study to support accelerated approval pathway for ImmunoGen's (IMGN) ovarian cancer candidate, mirvetuximab soravtansine. Shares up.

ImmunoGen (IMGN) Up 51.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Roche Gets CHMP Opinion for Breast Cancer & Lymphoma Drugs

by Zacks Equity Research

Roche's (RHHBY) breast cancer candidate and lymphona candidate get positive CHMP opinion. The company inks a deal to acquire Promedior, Inc.

ImmunoGen (IMGN) Q3 Earnings & Sales Beat, Shares Rally

by Zacks Equity Research

ImmunoGen (IMGN) reports narrower-than-expected third-quarter loss and beats revenue estimates. The company is set to initiate the FDA recommended phase III study on mirvetuximab soravtansine by year-end.

Company News for Nov 4, 2019

by Zacks Equity Research

Companies In The News Are: MOBL, GOOGL, IMGN, HMSY

ImmunoGen (IMGN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

ImmunoGen (IMGN) delivered earnings and revenue surprises of 21.05% and 45.18%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

ImmunoGen (IMGN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ImmunoGen (IMGN) Up 18.8% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Jazz Pharma (JAZZ) Q2 Earnings and Sales Beat Estimates

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) reports encouraging second-quarter 2019 earnings and revenues and raises its sales guidance for 2019.

ImmunoGen (IMGN) Stock Down Despite Q2 Earnings & Sales Beat

by Zacks Equity Research

ImmunoGen (IMGN) reports narrower-than-expected loss in the second quarter and beats revenue estimates. The company provides updated guidance for 2019.

ImmunoGen (IMGN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

ImmunoGen (IMGN) delivered earnings and revenue surprises of 9.38% and 50.46%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: ImmunoGen (IMGN) Q2 Earnings Expected to Decline

by Zacks Equity Research

ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will ImmunoGen Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor ImmunoGen.

Why Is ImmunoGen (IMGN) Down 26% Since Last Earnings Report?

by Zacks Equity Research

ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN

by Zacks Equity Research

Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

ImmunoGen Plunges as FDA Recommends New Study for Lead Drug

by Zacks Equity Research

FDA advises ImmunoGen (IMGN) to conduct a phase III study to evaluate the safety and efficacy of lead candidate - mirvetuximab soravtansine.

ImmunoGen (IMGN) Misses on Earnings & Revenues in Q1

by Zacks Equity Research

ImmunoGen (IMGN) reports wider-than-expected loss in Q1 and misses revenue estimates.

ImmunoGen (IMGN) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

ImmunoGen (IMGN) delivered earnings and revenue surprises of 3.23% and -14.13%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate ImmunoGen (IMGN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Options Traders Expect Huge Moves in ImmunoGen (IMGN) Stock

by Zacks Equity Research

Investors need to pay close attention to ImmunoGen (IMGN) stock based on the movements in the options market lately.

ImmunoGen (IMGN) Down 50.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biotech Stock Roundup: BIIB to Acquire Nightstar, Other Pipeline News & More

by Zacks Equity Research

Key highlights of the past week are merger agreements plus regulatory and pipeline developments.

Immunogen Ovarian Cancer Drug Fails in Phase III, Stock Sinks

by Zacks Equity Research

Immunogen's (IMGN) ovarian cancer candidate, mirvetuximab soravtansine fails to meet primary endpoint in a phase III monotherapy study. Shares of the company decline almost 47%.

ImmunoGen (IMGN) Beats on Earnings & Sales in Q4, Shares Up

by Zacks Equity Research

ImmunoGen (IMGN) reports narrower-than-expected loss in Q4 and beats revenue estimates.

Options Traders Expect Huge Moves in ImmunoGen (IMGN) Stock

by Zacks Equity Research

Investors need to pay close attention to ImmunoGen (IMGN) stock based on the movements in the options market lately.